game slot online gratis deposit

Saturday, December 14, 2024 Turkish Airlines will be among the first carriers to operate from John F. Kennedy International Airport’s New Terminal One when it opens in 2026. The airline will also unveil an exclusive, state-of-the-art lounge for its premium passengers, a key part of its ongoing expansion at this major U.S. hub. The New Terminal One, set to be the largest international terminal in the U.S., promises world-class amenities and cutting-edge technology, ensuring a superior travel experience. This major terminal development is part of the Port Authority of New York and New Jersey’s ambitious $19 billion overhaul of JFK Airport, which includes two new terminals, the modernization of existing ones, a new ground transportation center, and a streamlined roadway network for improved passenger flow. Currently operating 19 flights weekly between JFK and its Istanbul hub, Turkish Airlines will continue offering seamless connections to its global network from the new terminal. The airline’s 11,000-square-foot lounge will be twice the size of its existing space, featuring premium services, panoramic airfield views, and direct boarding access for business class passengers and top-tier frequent flyers. Recognized for its exceptional service, Turkish Airlines has recently earned the World Class Award from the Airline Passenger Experience Association (APEX) for the fourth consecutive year, joining just 10 airlines worldwide to receive this honor. “We are thrilled to welcome Turkish Airlines to the New Terminal One at JFK, where their commitment to world-class customer service aligns perfectly with our mission to provide an unparalleled customer experience,” said The New Terminal One Chief Executive Officer Jennifer Aument. “We look forward to working closely with our colleagues at Turkish Airlines to elevate the travel experience for customers from 2026 and beyond.” Turkish Airlines Chairman of the Board and Executive Committee, Prof. Ahmet Bolat, expressed his enthusiasm for the airline’s new partnership with JFK’s New Terminal One: “We are thrilled to bring Turkish Airlines’ world-class service to this state-of-the-art facility, enhancing our passengers’ travel experience with a luxurious new lounge. This move highlights our ongoing commitment to expanding our presence in the U.S. market.” The New Terminal One has also secured partnerships with several leading global carriers, including Air France, KLM, Etihad, LOT Polish Airlines, Korean Air, EVA Air, Air Serbia, SAS, Neos, and Philippine Airlines. In addition, Air China is joining forces with the terminal to elevate the experience for Chinese visitors to New York. Focused on enhancing the overall customer journey, the New Terminal One aims to deliver a seamless and exceptional experience by collaborating closely with airline partners across all passenger touchpoints. Once complete, the terminal will be JFK’s largest and will significantly increase widebody aircraft gate capacity, offering international airlines a unique opportunity to expand their services at this premier global gateway to the U.S.( MENAFN - 3BL) By Candace Higginbotham Ever heard of the benefits cliff? It's a term to describe the impact of a sudden or gradual decrease in public benefits that occurs when a family's income exceeds the eligibility threshold for an assistance program. People who participate in programs like Supplemental Nutrition Assistance Program (SNAP) and Children's health Insurance Program (CHIP) or receive childcare subsidies or child tax credits can face a benefits cliff when they get a raise, take a new job or simply work more hours. This seemingly positive wage increase can result in an individual making too much money to receive the benefits – but not enough to sustain themselves and their household. In short, their income gain results in them being worse off financially than before the income gain (a benefits cliff), or no better off (a benefits plateau). And that can have significant consequences for families and communities: it can keep people in low-wage jobs, discourage them from joining the workforce and influence other decisions that hold them back from long-term financial success. Education and workforce readiness is one of Regions Bank's community engagement priority areas and the bank offers wide-ranging support to community partners that provide job readiness programs, skills training and career coaching. These organizations are well aware of the benefits cliff problem – and the lack of simple solutions. So, as part of its Important Insights series, the Regions Making Life Better Institute® recently hosted a webinar to provide tools and information to help community partners prepare their clients for some of the difficult realities of career advancement. Regions invited Alex Ruder, Community and Economic Development director and principal adviser at the Federal Reserve Bank of Atlanta, to expand understanding of the benefits cliff. Ruder began the discussion with a case study that demonstrates the benefits cliff and plateau, by walking participants through a familiar example: A person working full-time in a near-minimum wage job participating in public assistance programs wants to enter the health care sector to increase their career and financial opportunities. He outlined points in the person's career trajectory where their net financial resources would actually decline or remain the same, even with pay raises, additional certifications and promotions. According to Ruder, there are three potential ways for nonprofits to assist clients who may face a benefits cliff in their journey from entry level to a living wage job. “Building skills, getting certifications and pursuing new roles are proven ways people can advance their career and increase economic mobility,” said Leroy Abrahams, head of Community Engagement at Regions.“Engaging in dialogue with our community partners and workforce development experts helps foster prosperity in our communities.” The webinar participants, representing community organizations around the country, welcomed the discussion and resources. “This has been a terrific presentation and really makes me think of new ways to have conversations that are simple and purposeful that contacts can understand and feel confident regarding their future,” said Dr. Douglas Stewart of the Tennessee College of Applied Technology. That's the reaction that Gina Sian, head of the Regions Making Life Better Institute, was hoping for. “Regions launched this program of free webinars four years ago to help our valuable community partners navigate challenges and provide technical assistance as they work toward their mission,” Sian said.“Investing in knowledge-sharing and skill-building opportunities like these deepen our understanding of the barriers that our communities face and helps us work collaboratively together toward meaningful solutions.” MENAFN13122024007202015466ID1108992037 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.game slot online gratis deposit 。

Jennifer Love Hewitt Will Return for ‘I Know What You Did Last Summer’

Mysterious googly eyes go viral after appearing on public art in Oregon

VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “ Company ”, “ Rakovina ”, or “ Rakovina Therapeutics ”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the closing of a $3.0 million private placement. The private placement consists of 50,000,000 units (the “ Units ”) at a price of $0.06 per Unit. Each Unit consists of one common share of the Company (each, a “ Common Share ”) and one Common Share purchase warrant (each, a “ Warrant ”). Each Warrant entitles the holder thereof to subscribe for and purchase one Common Share of the Company for a period of 24 months from the date of issue at a price of $0.10 per Common Share. Rakovina retains the right to accelerate the Warrant exercise period if, upon written notice to the holder, the 20-day volume-weighted average price of its Common Shares exceeds $0.30. In connection with the Private Placement, the Company paid cash finder’s fees to Canaccord Genuity Corp., Ventum Financial Corp., Haywood Securities Inc., Research Capital Corporation, Hampton Securities Limited, Ewing Morris & Co. Investment Partners Ltd. and Leede Financial Inc. (each a “ Finder ”, and collectively, the “ Finders ”) in the aggregate amount of $180,841 and issued a total of 3,021,872 non-transferable finder’s warrants (each, a “ Finder’s Warrant ’) to the Finders, in accordance with the policies of the TSX Venture Exchange (the “ TSXV ”). Each Finder’s Warrant entitles the holder thereof to subscribe for and purchase one Common share of the Company for a period of 24 months from the date of issue at a price of $0.10 per Common Share, subject to acceleration on the same terms as the Warrants issued in connection with the private placement. The private placement is subject to the final acceptance of the TSXV and all securities issuable in connection with the private placement are subject to a hold period of four months plus one day from the date of issuance, in accordance with applicable securities laws. The proceeds of the private placement will be used to accelerate both discovery and development of the Company’s proprietary drug candidates, shortlisted from the Deep Docking and Variational AI platforms. “This overwhelming response from our investors underscores the strength of our science, the extraordinary talent and dedication of our team and the transformative potential of our therapies,” said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics. “We are deeply grateful for the trust placed in us and remain resolute in our mission to utilize leading AI technologies to develop innovative solutions for cancer care.” The Company extends its heartfelt thanks to its investors, partners, and team for their unwavering support as Rakovina continues its work to bring new hope to patients and families affected by cancer. Rakovina is pleased to announce its engagement of Fairfax Partners Inc. as its Investor Relations (IR) partner. With extensive expertise in investor engagement strategies, Fairfax will implement a comprehensive six-month IR program designed to enhance Rakovina’s market presence and expand its investor base. The program, which includes an option to renew for an additional six months, focuses on complementing traditional IR efforts with targeted online marketing campaigns, activation of a robust social media influencer network, and collaboration with external consultants and global wealth management channels. These initiatives will support Rakovina’s strategic plan for 2025 by institutionalizing its investor base and strengthening its distribution capabilities. Under the agreement, Fairfax will receive a monthly fee of $5,000 plus GST, a one-time setup fee of $15,000 plus GST, and a marketing budget of $120,000 plus GST, disbursed as follows: $80,000 upon signing and $40,000 two months later. Services provided by Fairfax include inbound and outbound phone communications, website and social media management, marketing material preparation, news release support, and roadshow assistance, ensuring Rakovina’s IR efforts align with market expectations. Fairfax Partners Inc., located at 306-1238 Seymour Street, Vancouver, BC, confirms that neither its directors nor officers hold any securities of Rakovina. For inquiries, please contact connect@fairfaxpartners.com. “We are thrilled to partner with the seasoned team at Fairfax Partners to expand our investor base and increase awareness of Rakovina Therapeutics’ vision. Fairfax’s creative and forward-thinking approach to investor relations will be a critical asset as we enter a pivotal year. By harnessing their extensive network and digital expertise, we aim to significantly enhance our market presence and deliver lasting value to our shareholders,” said Mr. Bacha. About Rakovina Therapeutics Inc. Rakovina Therapeutics Inc. is dedicated to developing innovative cancer therapies targeting the DNA-damage response. The company has established a development pipeline of novel DNA-damage response inhibitors by leveraging Artificial Intelligence (AI) to accelerate the identification and optimization of drug candidates. Rakovina Therapeutics aims to advance one or more of these candidates into human clinical trials in collaboration with pharmaceutical partners and secure marketing approvals from Health Canada, the U.S. Food and Drug Administration, and other international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com . The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Notice Regarding Forward-Looking Statements: This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the terms of the private placement, the closing of the private placement, the receipt of final TSXV approval, the proposed business plan of the Company; the Company’s commitment to advancing new cancer therapies; the ability of the Company to extract value from its AI collaborations; the Company’s ability to execute on its business plans while maintaining high standards of research; the ability of Pharma Inventor Inc. to accurately provide medicinal chemistry support; the projected timeline and effectiveness of the Company’s strategy to utilize the Deep Docking AI platform; and the Company’s ability to generate shareholder value. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company’s most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company’s profile page at www.sedar.com. For Further Information Contact: David Hyman, Chief Financial Officer info@rakovinatherapeutics.com Invest Relations &Media Michelle Seltenrich ir@rakovinatherapeutics.com 778-773-5432Buying Advice: In search of health and happiness using the science of ergonomics